Fact CheckerSign in

NCT07180901Recruiting

Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer

Proactive Risk-based Optimization & Notifications for Treatment & Outcomes (PRONTO) in Head & Neck Cancer: A Strategy to Reduce Delays From Surgery to Post-Operative Adjuvant Therapy in Head and Neck Cancer

Source: ClinicalTrials.gov · Last updated 18 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Delays between surgery and the initiation of post-operative radiotherapy (S-PORT) in head and neck cancer (HNC) patients are prevalent and associated with worse oncologic outcomes. This pilot study evaluates whether a proactive, automated care coordination system (PRONTO-HN) can improve adherence to recommended S-PORT intervals of ≤42 days at the Centre hospitalier de l'Université de Montréal (CHUM). The study is a single-center, quasi-experimental, interrupted time-series design with two phases. Group A (control) includes patients treated before the intervention (using a prospectively maintained database from August 2024 to August 2025). Group B (intervention) includes patients treated with the new coordination system from September 2025 to September 2026. The intervention includes automated alerts, multidisciplinary task coordination, and risk stratification based on a predictive model developed and published by our team. This model uses only pre-operative data to estimate the likelihood that a patient will require adjuvant therapy after surgery, stratifying patients into high- and low-risk categories. High-risk patients receive intensified coordination protocols, including early oncology and dental consultations and shorter target times for pathology results. Primary objective: Reduce the proportion of patients with S-PORT \> 42 days. Secondary/tertiary objectives: Reduce mean S-PORT time. Evaluate impacts on overall, locoregional, and disease-free survival in a 2- and 3-year follow up study. Patients are identified at the time the operating room request is submitted. Demographic, clinical, and oncologic data are collected and stored securely in REDCap. As the intervention is administrative in nature and does not modify patient care, consent is waived. Statistical analysis will evaluate the intervention's effect and identify predictors of delays. A sample of 38 patients per group provides adequate power to detect a drop in S-PORT \> 42 days from 80% to 50%.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
85 (estimated)
First submitted
4 Aug 2025
Start date
21 Aug 2025
Primary completion date
21 Oct 2026
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
NCT number
NCT07180901

What you commit to

  • Study type: Interventional
  • Planned participants: 85
  • From 21 Aug 2025 to the primary completion date, 21 Oct 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients who do not end up receiving surgery.

Other

  • S-PORT \> 180 days

Who the study is looking for

  • All adult patients (age 18 or older).
  • Pathologically confirmed oral cavity or laryngeal squamous cell carcinoma.
  • Diagnosed from July 2024 to September 2026.
  • With planned primary intention surgical resection.
  • With or without adjuvant therapy.
  • Treated at the Centre Hospitalier de l'Université de Montréal.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Centre Hospitalier de l'Université de Montréal
Coordinator of this site? Confirm its status
MontrealCanadaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.